Spark Therapeutics Announces Updated Phase 1/2 Study Results Supporting the Durability of Investigational Gene Therapy SPK-8011 in Patients With Hemophilia A
December 12, 2022 12:00 ET
|
Spark Therapeutics, Inc.
Multi-year data, with up to five years of follow up, show sustained expression of FVIII in more than 90% of participants, in addition to improved annual bleeding and infusion ratesData shared during...
Bragar Eagel & Squire, P.C. is Investigating the Board of Directors of Spark Therapeutics, Inc. (ONCE) on Behalf of Stockholders and Encourages ONCE Investors to Contact the Firm
February 25, 2019 18:07 ET
|
Bragar Eagel & Squire
NEW YORK, Feb. 25, 2019 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C. is investigating potential claims against the board of directors of Spark Therapeutics, Inc. (NASDAQ: ONCE) on behalf of...
Spark Therapeutics Reports Full Year 2014 Financial Results
March 18, 2015 08:00 ET
|
Spark Therapeutics, Inc.
PHILADELPHIA, March 18, 2015 (GLOBE NEWSWIRE) -- Spark Therapeutics (Nasdaq:ONCE) today announced financial results for the year ended December 31, 2014.
"Following our successful initial public...